CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001
Go back to CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001| (NASDAQ: CRSP) | Delayed: 60.08 +4.46 (8.02%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.62 | 52 Week High | $18.88 | |||
| Open | $56.18 | 52 Week Low | $13.75 | |||
| Day High | $61.68 | P/E | N/A | |||
| Day Low | $56.18 | EPS | $0.00 | |||
| Volume | 2,931,689 | |||||
| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 528.04 +30.03 (6.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $498.01 | 52 Week High | $134.71 | |||
| Open | $503.76 | 52 Week Low | $73.31 | |||
| Day High | $529.14 | P/E | N/A | |||
| Day Low | $501.53 | EPS | $-1.98 | |||
| Volume | 1,879,133 | |||||
